百利天恒(688506.SH)：T-Bren(HER2 ADC)用于HER2阳性局部晚期或转移性胃或胃食管结合部腺癌患者纳入突破性治疗品种名单

Core Viewpoint - The company, Baillie Tianheng (688506.SH), has announced that its self-developed innovative biopharmaceutical T-Bren (HER2 ADC) shows significant anti-tumor efficacy in clinical trials and has been included in the list of breakthrough therapies by the National Medical Products Administration for patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed prior treatments [1] Group 1 - The innovative biopharmaceutical T-Bren targets HER2 and has best-in-class potential [1] - T-Bren has demonstrated significant anti-tumor efficacy in clinical trials [1] - The drug is specifically for patients who have failed first-line anti-HER2 treatment and standard chemotherapy [1]